According to The Insight Partners' research, the Europe Contract Research Organization (CRO) Market was valued at US$ 22,885.0 Million in 2024 and is expected to reach US$ 40,023.7 Million by 2031, registering a CAGR of 8.3% from 2024 to 2031.
Expansion of biologics and biosimilars and sustainability initiatives are among the critical factors attributed to the Europe contract research organization (cro) market.
The growth potential for the CRO market is largely supplemented by the upcoming biologics and biosimilars, mainly due to the increased competition from innovative therapies and the expired patents of blockbuster biologics. Biologics include product types such as monoclonal antibodies and recombinant proteins, and these will rule the landscape of biopharmaceuticals, mainly owing to their strengths in curing chronic and life-threatening diseases. With patent expiration for most biologics, the market for biosimilars, copies of biologics that are very similar and price-effective, is already developing rapidly. This is where the end; CROs stand to gain lucratively in outsourcing research and development for the faster delivery of biosimilars. According to the WHO, in February 2025, Biosimilars are viewed as an important part of expanding access to biologic therapies globally, especially as they can be as much as 60% less expensive than originator biologics. Due to increased manufacturing capacity and regulatory harmonization across countries, CROs are becoming more involved in global clinical trials, analytic studies, and regulatory submissions, each involving biologic and biosimilar products. This demand is changing the CRO landscape, establishing biologics and biosimilars as a platform for healthcare innovation.
Another factor is that the high cost and lengthy process of developing biologics attract outsourcing to CROs, with companies looking to cut costs and shorten time-to-market. CROs investing in advanced technologies, biologics, and biosimilar expertise should expect to profit most from this expanding pool. The world's push for financially affordable health solutions continues to fuel this growth, with the cost savings generated by biosimilars that are therapeutically equivalent to their reference biologics. Therefore, the continuous increase in biologics and biosimilars is exciting the market and stressing the importance of CROs in advancing biopharmaceutical development and helping to meet unmet medical needs.
Europe Contract Research Organization (CRO) Market Segmentation Analysis:
- By Service Type, the Europe Contract Research Organization (CRO) Market is segmented into Early Phase Development Services, Clinical Research Services, Laboratory Services, and Post-Approval Services. The Clinical Research Services segment is projected to expand at 8.6% CAGR during 2024 - 2031.
- By Product Type, the Europe Contract Research Organization (CRO) Market is segmented into Cell and Gene Therapy, Biosimilars, Antibody Drug Conjugates, and Others. The Biosimilars segment is projected to expand at 8.4% CAGR during 2024 - 2031
- By Type, the Europe Contract Research Organization (CRO) Market is segmented into In-house and Outsource. The Outsource segment is projected to expand at 8.5% CAGR during 2024 - 2031.
- By Application, the Europe Contract Research Organization (CRO) Market is segmented into Oncology, Neurology, Cardiology, Infectious Diseases, Metabolic Disorder, Nephrology, Respiratory, Dermatology, Ophthalmology, Hematology, and Others. The Oncology segment is projected to expand at 9.1% CAGR during 2024 - 2031.
- By End User, the Europe Contract Research Organization (CRO) Market is segmented into Pharmaceutical and Biotech Companies, Medical Device Companies, Academic and Research Institutes, and Others. The Pharmaceutical and Biotech Companies segment is projected to expand at 8.5% CAGR during 2024 - 2031.
By country, the Europe Contract Research Organization (CRO) Market is categorized into the United Kingdom, Germany, France, Italy, Spain, Netherlands, Greece, and the Rest of Europe. The Rest of Europe is projected to expand at 7.1% CAGR during 2024 - 2031.
Key players operating in the Contract Research Organization (CRO) Market are Parexel International Corp, IQVIA Holdings Inc, Syneos Health Inc, Medpace Holdings Inc, Thermo Fisher Scientific (PPD Inc), ProPharma Group, Precision Medicine Group, LLC., O4 Research Ltd, Julius Clinical, Siron Clinical, Clinmark sp. z o.o., Pharmaxi LLC, Smerud Medical Research Group, AURIGON GMBH, among others.
In Nov-2023, Julius Clinical Research announced a majority recapitalization by Ampersand Capital Partners ("Ampersand"). The investment and partnership with Ampersand enables the Company to expand its scientific and therapeutic expertise as well as build its geographic footprint in Europe and North America to accelerate the growth of its CRO services.
Contact Us
Phone: +1-646-491-9876
Email Id: sales@theinsightpartners.com